Certain chemical entities, compositions and methods
Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
1. A compound of the Formula 406:
or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt thereof, wherein:
R′ is a moiety of Formula II:
wherein W c is aryl, heteroaryl, heterocycloalkyl, or cycloalkyl;
q is an integer of 0, 1, 2, 3, or 4;
R 1 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, amido, alkoxycarbonyl, sulfonamido, halo, cyano, or nitro;
each instance of R 2 is independently alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, heteroarylalkyl, alkoxy, amino, halo, cyano, hydroxy or nitro;
R 3 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, amido, amino, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, or nitro; and
R 9 is hydrogen, C 1-10 alkyl, cycloalkyl, or hetercycloalkyl.
2. The compound of claim 1 , wherein R 3 is hydrogen, alkyl, or halo.
3. The compound of claim 2 , wherein R 3 is —H, —CH 3 , —CH 2 CH 3 , —CF 3 , —Cl or —F.
4. The compound of claim 3 , wherein R 3 is methyl.
5. The compound of claim 3 , wherein R 3 is chloro.
6. The compound of claim 1 , wherein W c is aryl.
7. The compound of claim 1 , wherein R 9 is C 1-10 alkyl.
8. The compound of claim 1 , wherein the compound is a compound of Formula 406A:
or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt thereof.
9. The compound of claim 8 , wherein the compound is a compound of Formula 1304:
10. The compound of claim 9 , wherein R′ is
11. The compound of claim 10 , wherein R 3 is chloro.
12. The compound of claim 1 , which is Compound 4704:
13. The compound of claim 1 , which is Compound 5003:
14. The compound of claim 1 , which is Compound 5009:
15. A compound of the Formula 405:
or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt thereof, wherein:
R′ is a moiety of Formula II:
wherein W c is aryl, heteroaryl, heterocycloalkyl, or cycloalkyl;
q is an integer of 0, 1, 2, 3, or 4;
R 1 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, amido, alkoxycarbonyl, sulfonamido, halo, cyano, or nitro;
each instance of R 2 is independently alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, heteroarylalkyl, alkoxy, amino, halo, cyano hydroxy or nitro;
R 3 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, amido, amino, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxyl, or nitro; and
R 9 is hydrogen, C 1-10 alkyl, cycloalkyl, or hetercycloalkyl.
16. The compound of claim 15 , wherein the compound is a compound of Formula 405A:
or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt thereof.